Anavex Lf SC Cm (AVXL) 3.76 $AVXL
Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients Presented at AAIC 2016
GlobeNewswire - Fri Jul 29, 8:20AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), confirms the information in the July 27, 2016 press release announcing positive results from the Phase 2a Alzheimer's trial for ANAVEX 2-73.
AVXL: 3.76 (+0.25)
Anavex Presents 31-Week Efficacy Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients at AAIC 2016
GlobeNewswire - Wed Jul 27, 12:00PM CDT
Sustained Response Through 31 Weeks for both Cognitive (MMSE) and Functional (ADCS-ADL) Measures
AVXL: 3.76 (+0.25)
Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients at AAIC 2016
GlobeNewswire - Sun Jul 24, 8:30AM CDT
Results Feature Favorable Safety, Maximum Tolerated Dose, Positive Dose Response as well as Positive Unexpected Therapeutic Response Events
AVXL: 3.76 (+0.25)
Coverage Initiated on Select Healthcare Stocks
ACCESSWIRE - Thu Jul 14, 8:17AM CDT
LONDON, UK / ACCESSWIRE / July 14, 2016 / Active Wall St. announces the list of stocks for today's coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Healthcare sector. Companies recently under review include Shire, Novartis, Anavex Life Sciences, and Impax Laboratories. See our complete notes on Shire at:
IPXL: 31.28 (-0.19), AVXL: 3.76 (+0.25), SHPG: 193.72 (+2.29), NVS: 83.09 (+1.01)
Anavex to Present at the Alzheimer's Association International Conference (AAIC) 2016
GlobeNewswire - Tue Jul 12, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that data related to ANAVEX 2-73, the Company's lead product candidate, will be presented in two poster presentations at the upcoming Alzheimer's Association International Conference(R) 2016 (AAIC(R)) to be held from 24-28 July, 2016 in Toronto, Canada.
AVXL: 3.76 (+0.25)
Kite (KITE) Enrolls ZUMA-1 Study, Interim Data, Filing in 2016
Arpita Dutt - Zacks Investment Research - Fri Jul 08, 8:03AM CDT
Kite (KITE) has finished enrolling patients in the diffuse large B-cell lymphoma cohort of the phase II portion of the ZUMA-1 study on KTE-C19.
AVXL: 3.76 (+0.25), INVA: 13.16 (+1.46), KITE: 57.14 (+2.62), FCSC: 1.09 (unch)
BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 9.1%
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 7:40AM CDT
BioMarin Pharmaceutical Inc. (BMRN) saw its shares rise above 9% in the last trading session.
BMRN: 98.81 (+0.61), AVXL: 3.76 (+0.25)
Kura Oncology (KURA) Looks Good: Stock Adds 5.4% in Session
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 7:00AM CDT
Kura Oncology, Inc. (KURA) was a big mover last session, as the company's shares rose over 5% on the day.
AVXL: 3.76 (+0.25), KURA: 4.02 (+0.06)
Anavex's Lead Candidate Gets Orphan Drug Status Yet Again
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:22PM CDT
Anavex Life Sciences (AVXL) announced that ANAVEX 2-73 has been granted orphan drug status by the FDA for the treatment of infantile spasms.
AVXL: 3.76 (+0.25), ANIP: 60.61 (+1.00), RTRX: 17.89 (+0.36), ACOR: 25.46 (+0.51)
Anavex Announces U.S. FDA Orphan Drug Designation for ANAVEX 2-73 for Treatment of Infantile Spasms
GlobeNewswire - Wed Jun 22, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reports the U.S. Food and Drug Administration's Office of Orphan Product Development has granted Orphan Drug Designation to ANAVEX 2-73 for the treatment of infantile spasms.
AVXL: 3.76 (+0.25)
Coverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and Anavex Life Sciences
PR Newswire - Fri Jun 10, 6:45AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Anavex Life Sciences Corporation (NASDAQ: AVXL). Learn more about these stocks by accessing their free trade alerts at:
DVAX: 15.53 (+0.03), PACB: 8.54 (-0.06), AVXL: 3.76 (+0.25), PPHM: 0.36 (-0.02)
Market Has Not Yet Noticed Potential in Anavex Life Sciences (AVXL); Have You?
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 7:48AM CDT
Anavex Life Sciences is seeing solid earnings estimate revisions and has an impressive Zacks Rank but that is not yet reflected in its price
AVXL: 3.76 (+0.25)
Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X - Autism-Related Disorders
GlobeNewswire - Mon Jun 06, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced positive data of ANAVEX 2-73 in an exploratory study in a Fragile X syndrome model presented at the Gordon Research Conference for Fragile X and Autism-Related Disorders, being held June 5-10, 2016 in Mount Snow, VT.
AVXL: 3.76 (+0.25)
Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX 2-73 for the Treatment of Rett Syndrome
GlobeNewswire - Fri May 20, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reports the U.S. Food and Drug Administration's (FDA) Office of Orphan Product Development (OOPD) has granted Orphan Drug Designation (ODD) to ANAVEX 2-73 for the treatment of Rett syndrome.
AVXL: 3.76 (+0.25)
Anavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms
GlobeNewswire - Wed May 18, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, announces today that treatment with ANAVEX 2-73 significantly reduced the number of spasms in an animal model with infantile spasms (epileptic spasms) in infant rats.
AVXL: 3.76 (+0.25)
Anavex Life Sciences reports 2Q loss
Automated Insights - Wed May 11, 6:15AM CDT
NEW YORK (AP) _ Anavex Life Sciences Corp. (AVXL) on Wednesday reported a loss of $2 million in its fiscal second quarter.
AVXL: 3.76 (+0.25)
Anavex Reports Fiscal Second Quarter 2016 Financial Results
GlobeNewswire - Wed May 11, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three and six months ended March 31, 2016.
AVXL: 3.76 (+0.25)
Could a Pill to Cure Alzheimer's Disease Become Available Soon?
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 26, 3:22PM CDT
Image source: Anavex Life Sciences. Recently, two women in Melbourne with Alzheimer's disease found themselves able to complete complex tasks they haven't been capable of for some time. One woman found herself suddenly able to play the piano again,...
AVXL: 3.76 (+0.25)
4 Stocks That Are Making Huge Gains Today
ACCESSWIRE - Mon Apr 25, 9:45AM CDT
NEW YORK, NY / ACCESSWIRE / April 25, 2016 / The Stock Expert is issuing a report on four stocks that are performing well this Friday. TPUB, AVXL, NEOT and LGCY are on high breakout alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
LGCY: 1.71 (+0.05), TPUB: 13.96 (+0.17), AVXL: 3.76 (+0.25), NEOT: 1.04 (-0.05)
U.S. FDA Grants Orphan Drug Designation to ANAVEX 3-71 for the Treatment of Frontotemporal Dementia
GlobeNewswire - Fri Apr 08, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ANAVEX 3-71 for the treatment of Frontotemporal dementia (FTD).
AVXL: 3.76 (+0.25)
Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients Presented at AAIC 2016
GlobeNewswire - Fri Jul 29, 8:20AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), confirms the information in the July 27, 2016 press release announcing positive results from the Phase 2a Alzheimer's trial for ANAVEX 2-73. AVXL: 3.76 (+0.25)
Anavex Presents 31-Week Efficacy Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients at AAIC 2016
GlobeNewswire - Wed Jul 27, 12:00PM CDT
Sustained Response Through 31 Weeks for both Cognitive (MMSE) and Functional (ADCS-ADL) Measures
AVXL: 3.76 (+0.25)
Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients at AAIC 2016
GlobeNewswire - Sun Jul 24, 8:30AM CDT
Results Feature Favorable Safety, Maximum Tolerated Dose, Positive Dose Response as well as Positive Unexpected Therapeutic Response Events
AVXL: 3.76 (+0.25)
Coverage Initiated on Select Healthcare Stocks
ACCESSWIRE - Thu Jul 14, 8:17AM CDT
LONDON, UK / ACCESSWIRE / July 14, 2016 / Active Wall St. announces the list of stocks for today's coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Healthcare sector. Companies recently under review include Shire, Novartis, Anavex Life Sciences, and Impax Laboratories. See our complete notes on Shire at:
IPXL: 31.28 (-0.19), AVXL: 3.76 (+0.25), SHPG: 193.72 (+2.29), NVS: 83.09 (+1.01)
Anavex to Present at the Alzheimer's Association International Conference (AAIC) 2016
GlobeNewswire - Tue Jul 12, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that data related to ANAVEX 2-73, the Company's lead product candidate, will be presented in two poster presentations at the upcoming Alzheimer's Association International Conference(R) 2016 (AAIC(R)) to be held from 24-28 July, 2016 in Toronto, Canada. AVXL: 3.76 (+0.25)
Kite (KITE) Enrolls ZUMA-1 Study, Interim Data, Filing in 2016
Arpita Dutt - Zacks Investment Research - Fri Jul 08, 8:03AM CDT
Kite (KITE) has finished enrolling patients in the diffuse large B-cell lymphoma cohort of the phase II portion of the ZUMA-1 study on KTE-C19.
AVXL: 3.76 (+0.25), INVA: 13.16 (+1.46), KITE: 57.14 (+2.62), FCSC: 1.09 (unch)
BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 9.1%
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 7:40AM CDT
BioMarin Pharmaceutical Inc. (BMRN) saw its shares rise above 9% in the last trading session.
BMRN: 98.81 (+0.61), AVXL: 3.76 (+0.25)
Kura Oncology (KURA) Looks Good: Stock Adds 5.4% in Session
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 7:00AM CDT
Kura Oncology, Inc. (KURA) was a big mover last session, as the company's shares rose over 5% on the day.
AVXL: 3.76 (+0.25), KURA: 4.02 (+0.06)
Anavex's Lead Candidate Gets Orphan Drug Status Yet Again
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:22PM CDT
Anavex Life Sciences (AVXL) announced that ANAVEX 2-73 has been granted orphan drug status by the FDA for the treatment of infantile spasms.
AVXL: 3.76 (+0.25), ANIP: 60.61 (+1.00), RTRX: 17.89 (+0.36), ACOR: 25.46 (+0.51)
Anavex Announces U.S. FDA Orphan Drug Designation for ANAVEX 2-73 for Treatment of Infantile Spasms
GlobeNewswire - Wed Jun 22, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reports the U.S. Food and Drug Administration's Office of Orphan Product Development has granted Orphan Drug Designation to ANAVEX 2-73 for the treatment of infantile spasms. AVXL: 3.76 (+0.25)
Coverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and Anavex Life Sciences
PR Newswire - Fri Jun 10, 6:45AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Anavex Life Sciences Corporation (NASDAQ: AVXL). Learn more about these stocks by accessing their free trade alerts at:
DVAX: 15.53 (+0.03), PACB: 8.54 (-0.06), AVXL: 3.76 (+0.25), PPHM: 0.36 (-0.02)
Market Has Not Yet Noticed Potential in Anavex Life Sciences (AVXL); Have You?
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 7:48AM CDT
Anavex Life Sciences is seeing solid earnings estimate revisions and has an impressive Zacks Rank but that is not yet reflected in its price
AVXL: 3.76 (+0.25)
Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X - Autism-Related Disorders
GlobeNewswire - Mon Jun 06, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced positive data of ANAVEX 2-73 in an exploratory study in a Fragile X syndrome model presented at the Gordon Research Conference for Fragile X and Autism-Related Disorders, being held June 5-10, 2016 in Mount Snow, VT. AVXL: 3.76 (+0.25)
Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX 2-73 for the Treatment of Rett Syndrome
GlobeNewswire - Fri May 20, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reports the U.S. Food and Drug Administration's (FDA) Office of Orphan Product Development (OOPD) has granted Orphan Drug Designation (ODD) to ANAVEX 2-73 for the treatment of Rett syndrome. AVXL: 3.76 (+0.25)
Anavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms
GlobeNewswire - Wed May 18, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, announces today that treatment with ANAVEX 2-73 significantly reduced the number of spasms in an animal model with infantile spasms (epileptic spasms) in infant rats. AVXL: 3.76 (+0.25)
Anavex Life Sciences reports 2Q loss
Automated Insights - Wed May 11, 6:15AM CDT
NEW YORK (AP) _ Anavex Life Sciences Corp. (AVXL) on Wednesday reported a loss of $2 million in its fiscal second quarter.
AVXL: 3.76 (+0.25)
Anavex Reports Fiscal Second Quarter 2016 Financial Results
GlobeNewswire - Wed May 11, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three and six months ended March 31, 2016. AVXL: 3.76 (+0.25)
Could a Pill to Cure Alzheimer's Disease Become Available Soon?
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 26, 3:22PM CDT
Image source: Anavex Life Sciences. Recently, two women in Melbourne with Alzheimer's disease found themselves able to complete complex tasks they haven't been capable of for some time. One woman found herself suddenly able to play the piano again,...
AVXL: 3.76 (+0.25)
4 Stocks That Are Making Huge Gains Today
ACCESSWIRE - Mon Apr 25, 9:45AM CDT
NEW YORK, NY / ACCESSWIRE / April 25, 2016 / The Stock Expert is issuing a report on four stocks that are performing well this Friday. TPUB, AVXL, NEOT and LGCY are on high breakout alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
LGCY: 1.71 (+0.05), TPUB: 13.96 (+0.17), AVXL: 3.76 (+0.25), NEOT: 1.04 (-0.05)
U.S. FDA Grants Orphan Drug Designation to ANAVEX 3-71 for the Treatment of Frontotemporal Dementia
GlobeNewswire - Fri Apr 08, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ANAVEX 3-71 for the treatment of Frontotemporal dementia (FTD). AVXL: 3.76 (+0.25)
